Turnstone Biologics Corp - רווח נקי למניה בארבעת הרבעונים האחרונים TSBX

Turnstone Biologics (TSBX) is implementing robotic genome screening to accelerate drug synthesis, leveraging a substantial capital reserve to develop cancer vaccines. The annual EPS growth rate over the last 12 months reflects profit dynamics, where the value of serves as the current metric. Growth prospects are driven by a unique TIL-cell selection method and the test results of the TIDAL-01 drug in partnership with global clinics.
TSBX (Turnstone Biologics Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Turnstone Biologics investments in a staff of specialized oncologists and grant support determine the expenditure structure during early-stage testing. The rolling year earnings per share trend, reaching , measures the efficiency of cash flow regeneration and the ability to cover liabilities. The analyst utilizes this metric to assess the pace of business recovery following a downturn. Growth in EPS TTM allows for the differentiation of real profitability from accounting adjustments. Monitor the annual EPS TTM increase to verify the speed of the issuer's financial recovery.